LM
CNTX icon

Luminus Management’s Context Therapeutics CNTX Stock Holding History

Luminus Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-328,222
Closed -$215K – 22
2025
Q2 		$215K Buy
+328,222
New +$236K 0.06% 18

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Luminus Management's CNTX Position: Q3 2025 in Review

Luminus Management sold out of Context Therapeutics (CNTX) in Q3 2025, closing a stake of 328,222 shares — an estimated $215K sold.

Luminus Management first reported a position in CNTX in Q2 2025 and held it in 1 quarter. The position peaked at $215K in Q2 2025. 37 funds tracked by Wall St. Rank hold CNTX as of Q3 2025.

  • Luminus Management reported no remaining Context Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Luminus Management sold 328,222 Context Therapeutics shares in Q3 2025, an estimated $215K.
  • Luminus Management first reported a position in Context Therapeutics in Q2 2025 and held it in 1 quarter.
  • Luminus Management's Context Therapeutics position peaked at $215K in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2025.

Based on Luminus Management's 13F filing for Q3 2025, filed 3 Oct 2025.